BioMarin updates plans for three late-stage programs

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) gave R&D updates on three late-stage programs: achondroplasia therapy vosoritide ( BMN 111), phenylketonuria (PKU) treatment pegvaliase ( BMN 165), and cerliponase alfa ( BMN 190) to treat late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a form of Batten disease.

The updates came at the company's R&D day on Wednesday. BioMarin also unveiled the first clinical data for its hemophilia A gene therapy program (see above). ...